UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
AMENDMENT NO. 1 TO CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 20, 2006 (December 19, 2006)
Altus Pharmaceuticals Inc.
(Exact Name of Registrant as Specified in Charter)
| |
|
|
|
|
| Delaware
|
|
0-51711
|
|
04-3573277 |
|
|
|
|
|
|
(State or Other Juris-
diction of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.) |
| |
|
|
| 125 Sidney Street, Cambridge, Massachusetts
|
|
02139 |
|
|
|
|
| (Address of Principal Executive Offices)
|
|
(Zip Code) |
Registrant’s telephone number, including area code: 617-299-2900
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
|
|
|
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
TABLE OF CONTENTS
INTRODUCTORY NOTE
On December 20, 2006, Altus Pharmaceuticals Inc. (the “Company”) issued a press release
announcing a strategic collaboration with Genentech, Inc., and filed a Current Report on Form 8-K
dated December 19, 2006 (the “Current Report”) with the Securities and Exchange Commission that
included a copy of such press release. The Current Report inadvertently set forth the disclosure
under Item 8.01 of Form 8-K instead of Item 7.01 of Form 8-K.
The Company hereby amends and restates the Current Report in its entirety to read as follows:
Item 7.01. Regulation FD Disclosure.
On December 20, 2006, Altus Pharmaceuticals Inc. (the “Company”) issued a press release announcing
it has entered into an exclusive strategic collaboration with Genentech, Inc. to develop and
commercialize ALTU-238, the Company’s long-acting, crystalline form of human growth hormone. A copy
of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1 and
incorporated herein by reference.
The Company will hold a conference call and simultaneous webcast today, Wednesday, December 20,
2006 at 11:00 a.m. eastern time. A replay of the webcast will be available on www.altus.com through
January 20, 2007. Alternatively, the replay will be available starting at 3:00 p.m. eastern time on
December 20, 2006 through 11:59 p.m. eastern time Wednesday, December 27, 2006 by dialing (719)
457-0820 or (888) 203-1112. The replay passcode is 6959149.
The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or
otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly
set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The following exhibit relating to Item 7.01 shall be deemed furnished, and not filed:
99.1 Press Release dated December 20, 2006